{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02695160: Phase 1 Interventional Terminated Hemophilia B
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:lenzumestrocel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:olitresgene autoleucel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02396342: Phase 1/Phase 2 Interventional Completed Hemophilia B
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:ranuzifigene civaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03406104: Phase 3 Interventional Completed Leber Hereditary Optic Neuropathy
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:eretidigene velentivec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:dabocemagene autoficel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03041324: Phase 1/Phase 2 Interventional Terminated Mucopolysaccharidosis II
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE